CDC pushes anthrax protocol
===========================

The CDC has requested that all clinical and public health laboratories become familiar with the their protocol for handling suspected anthrax cases. The recommendations are fully detailed laboratory procedures concerning the collection of specimens, including types of specimens, required materials, and transportation; procedures for specimen processing and decontamination; procedures for handling, incubation, examination, and processing of cultures; differential tests for the presumptive identification of *Bacillus anthracis*; reporting procedures; and actions tobe taken if a presumptive identificationis made, especially if the organism is suspected to be a bioterrorist threat agent. The full protocol can be seen at *<http://www.bt.cdc.gov/Agent/Anthrax20010417.pdf>*. In November, 2001, (*Morb. Mortal. Wkly. Rep. 50: 941-948*) the CDC has published interim guidelines for clinicians for the clinical evaluation of persons suspected of having cutaneous or inhalation anthrax.

Human HIV vaccine trial begins
==============================

Investigators will begin testing an experimental HIV vaccine on human volunteers in South Africa, a country where more than 10% of the population is infected with the AIDS virus. The vaccine, which is also being tested in the United States, is one of about two dozen potential vaccines being testedon some 12,000 human volunteers in experiments around the world and is the only one that contains genetic material from the HIV strain most prevalent in South Africa.

The vaccine contains parts of a weakened strain of Venezuelan equine encephalitis and a harmless gene from a South African HIV strain. Scientists hope that by entering human cells, it will stimulate the production of antibodies that will fight off AIDS infections and also train specialized cells, dubbed killer T cells, to identify and eliminate infected cells after someone contracts the virus. The first human trials are aimed at establishing the safety of the preparation and are expected to last 2 years. Last February, an advanced human vaccine experiment involving 5,000 volunteers failed. Details can be seen at *<http://www.ajcp.com/headlines/news/200311031.html>*.

Contamination of meat and poultry decreasing
============================================

Agriculture Secretary Ann M. Veneman recently reported that therate of *Salmonella* detected in raw meat and poultry dropped by 66% over the past 6 years and by 16% compared with 2002. The U.S. Department of Agriculture (USDA) Food Safety and Inspection Service (FSIS) is the public health regulatory agency responsible for ensuring that meat, poultry, and egg products are safe, wholesome, and accurately labeled. Of the random samples collected and analyzed between 1 January and 31 October, 2003 by FSIS, 3.6% tested positive for *Salmonella* compared with 4.29% in 2002, 5.03% in 2001, 5.31% in 2000, 7.26% in 1999, and 10.65% in 1998. There were similar reductions in the amount of *E. coli* O157:H7 in ground beef and the USDA-reported *Listeria monocytogenes* in ready-to-eat meat and poultry products. Earlier this year, the USDA outlined a series of new, science-based initiatives to better understand, predict, and prevent microbiological contamination of meat and poultry products, thereby improving health outcomes for American families. The USDA report is available at *<http://www.usda.gov/news/releases/2003/11/0396.htm>.*

NIH launches ebola vaccine program
==================================

An NIH nurse became the first person ever injected with an experimental vaccine designed to protect against Ebola. Only two people have volunteered to be part of the NIH effort; the other volunteer is a landscaper who works in a nearby suburban neighborhood. NIH is seeking more people to participate in initial safety tests. This first Ebola vaccine was made withouta single component coming from the virus itself. Researchers at Vical (San Diego, CA), a biotechnology company, made the laboratory-synthesized strands of DNA mimic those found in the Ebola virus. Key components of the virus were removed, including that which triggers the illness and that which might allow the DNA to recombine with another virus\' DNA to form a new and potentially disease-causing virus. When injected, the DNA enters subcutaneous skin cells, where Ebola proteins are subsequently made. Immune-system cells attack those proteins and then are primed forever to fight a real Ebola infection. Blood tests will track the volunteers\' immune-system responses fora year. Much larger human studies will eventually be conducted to provide final proof that the vaccine is safe for large populations. More information can be seen at *<http://www.cidrap.umn.edu/cidrap/content/bt/vhf/news/nov1803ebola.html>.*

Syphilis again on the rise
==========================

After more than a decade of decreasing rates, the number of reported syphilis cases is increasing. The CDC reports that there have been more outbreaks of the STD among gay and bisexual men, especially in large cities. The trend also suggests a resurgence in other STDs, notably HIV disease. The syphilis rate increased from 2.1 cases per 100,000 individuals in 2000 to 2.2 in 2002; two thirds of the new cases were in gay and bisexual men. The information was presented at a National STD Prevention Conference held in Milwaukee in December. Cities reporting increased rates of STDs include Seattle, Chicago, Denver, and San Francisco. Several researchers noted that STD increases among gay and bisexual men might be due to increased risky sexual behavior following the success of antiretroviral therapy for treating HIV/AIDS and the perception that HIV is no longer a serious problem. Many researchers also called for new and effective approaches to prevent STDs in this population group. Summaries of key studies presented at the conference can be seen at *<http://www.thebody.com/cdc/std/gay_std.html>.*

ASM publishes shipping and bioterrorism plans
=============================================

The ASM\'s Professional Affairs Committee has posted the Packaging and Shipping of Infectious Substances for Sentinel Laboratories (formerly Level A) on its website. Larry Gray (Trihealth, Cincinnati, OH) authoredthe protocol, the contents of which represent the latest guidelines for packing and shipping of diagnostic and infectious substances. In addition, the Clinical Laboratory Bioterrorism Readiness Plan, developed by Susan Sharp (Kaiser, Portland, OR) and Dan Shapiro (Boston Medical Center, Boston, MA), was also recently posted on ASM\'s web site. The purpose of the Clinical Laboratory Bioterrorism Readiness Plan, or"BT Template," is to provide a model for laboratories to use for developing a bioterrorism (BT) preparedness plan. To download these and other Sentinel Guidelines, go to *<http://www.asm.org/Policy/index.asp?bid=6342>.*

CDC guidelines for collecting specimens from potential SARS patients
====================================================================

The CDC released a revised guideline for the collection of specimensfor the detection of corona virus (CoV) from potential SARS patients. The document updates and replaces the guidelines for specimen collection posted previously on CDC\'s SARS web siteto reflect the most recent information on laboratory diagnostics for SARS-CoV. The main changes are as follows: addition of stool, serum, and plasma to the list of specimens for RT-PCR testing; addition of information on the optimal timing of specimen collection and testing by specimen type; and recommendations to collect multiple specimens for RT-PCR testing. For more information, go to *<http://www.cdc.gov/ncidod/sars/specimen_collection_sars2.htm>.* Guidelines and recommendations for SARS surveillance, evaluation, and reporting in the absence of SARS-CoV transmission still apply. Also, see the CDC document, *In the Absence of SARS-CoV Transmission Worldwide: Guidance for Surveillance, Clinical and Laboratory Evaluation, and Reporting* which can be downloaded by going to *<http://www.cdc.gov/ncidod/sars/absenceofsars.htm>.*

New case definition for SARS
============================

The CDC has revised its case definition for SARS. The revised SARS case definition modifies the clinical, epidemiologic, laboratory, and case exclusion criteria in the U.S. surveillance case definition used during the 2003 epidemic. In the clinical criteria, the term "early" illness replaces "asymptomatic" or "mild" illness. The epidemiologic criteria include two new categories: (i) possible exposure to SARS-CoV and (ii) likely exposure to SARS-CoV. Laboratory criteria for evidence of SARS-CoV infection reflect advances in testing technology. The case-exclusion criteria have been changed to allow exclusion when a serum sample collected more than 28 days after onset of symptoms is negative for antibody to SARS-CoV. The revised case definition also classifies each SARS case as either a SARS report under investigation (SARS RUI) or SARS-CoV disease. For more information, go to *<http://www.cdc.gov/ncidod/sars/casedefinition.htm>*.

New test for identifying anthrax approved
=========================================

The FDA has cleared the Redline Alert (Tetracore, Inc., Gaithersburg, MD), a new immunoassay test kit for clinical laboratories to use with culture testing to help distinguish the organism that causes anthrax disease from similar organisms. Designed to be used with other laboratory tests, the Redline Alertcan be performed in about 15 minutes on the colonial growth of the organism and does not require specially trained personnel or special instrumentation. If the Redline Alert test is positive and other culture characteristics are consistent with this organism, it is likely that the person from whom the cultured cells were taken is infected with *B. anthracis.* Other testing is needed to definitively identify *B. anthracis*. A negative result with the new test cannot rule out anthrax, because in rare cases certain *B. anthracis* organisms may not give a positive result. However, according to the FDA, Redline Alert is not intended for use by all laboratories, only those whose staff is trained and proficient with microbiological culture procedures and who use Biological Safety Level 2 practices. To see the announcement, go to *<http://www.fda.gov/bbs/topics/NEWS/2003/NEW00992.html>.*

Anthrax vaccine is safe and effective
=====================================

The FDA published a final ruling concluding that the licensed anthrax vaccine is both safe and effective for prevention of anthrax disease, regardless of the route of exposure. The anthrax vaccine was first licensed in 1970. The ruling is part of the continuing review of biological products licensed before 1972, when responsibility for licensing these products moved to FDA from the NIH. The announcement can be viewed at *<http://www.fda.gov/bbs/topics/NEWS/2003/NEW01001.html>.*

New CLIA Appendix C published
=============================

The Centers for Medicare and Medicaid Services announced the publication of its revised *Survey Procedures and Interpretive Guidelines for Laboratories and Laboratory Services* (Appendix C of the State Operations Manual). Portions of this document were rewritten due to publication of CMS-2226-F:42 CFR 493 *Medicare, Medicaid, and CLIA Programs, Laboratory Requirements Relating to Quality Systems and Certain Personnel Qualifications, Final Rule*, on 24 January, 2003, which was effective April 24, 2003. Some of the topics the new document covers are policies for conducting surveys, provisions for proficiency testing, quality systems for non-waived testing, and issues relating to pre-analytic and analytic systems and new personnel. Specific information and links can be found at *<http://cms.hhs.gov/clia/appendc.asp>.*

New rules for mad cow disease
=============================

The USDA unveiled a series of new measures designed to minimize the risk of bovine spongiform encephalopathy (BSE, or mad cow disease) to humans. The new regulations (i) ban disabled (downer) cows from human food, (ii) ban the labeling of meat tested for BSE as "inspected and passed" before a negative test result is obtained, (iii) ban high-risk animal parts from animals \>30 months of age from human food, (iv) prohibit labeling as meat tissue culled from bones under high pressure, (v) ban air-injection stunning as a method of killing, (vi) ban mechanically separated meat in human food, and (vii) develop a nationwide system to identify animals in the food supply chain. Details are available from the USDA: *<http://www.usda.gov>.*
